We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
Cap. Flow
+$11.7M
Cap. Flow %
0.5%
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M
2
MDT icon
Medtronic
MDT
+$13.3M
3
UNH icon
UnitedHealth
UNH
+$8.16M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.42M
5
PFE icon
Pfizer
PFE
+$7.12M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$17M
2
AZN icon
AstraZeneca
AZN
+$11.3M
3
IDXX icon
Idexx Laboratories
IDXX
+$10.4M
4
VTRS icon
Viatris
VTRS
+$8.21M
5
OHI icon
Omega Healthcare
OHI
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Real Estate 2.48%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
26
Danaher
DHR
$138B
$21.6M 0.92%
236,170
– –
ZTS icon
27
Zoetis
ZTS
$31.9B
$21.5M 0.92%
251,415
+24,000
+11% +$2.16M
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.64B
$20.9M 0.9%
191,837
-31,345
-14% -$3.92M
HUM icon
29
Humana
HUM
$44B
$19.6M 0.84%
68,487
– –
CNC icon
30
Centene
CNC
$30.1B
$19.2M 0.82%
333,738
– –
ISRG icon
31
Intuitive Surgical
ISRG
$126B
$18.8M 0.8%
117,687
+43,800
+59% +$7.42M
TEVA icon
32
Teva Pharmaceuticals
TEVA
$41.2B
$18.7M 0.8%
1,211,868
+278,920
+30% +$5.72M
BMRN icon
33
BioMarin Pharmaceuticals
BMRN
$11.7B
$17.7M 0.76%
207,434
+66,896
+48% +$6.36M
AZN icon
34
AstraZeneca
AZN
$266B
$16.3M 0.7%
214,012
-145,300
-40% -$11.3M
BSX icon
35
Boston Scientific
BSX
$68.4B
$15.7M 0.67%
444,991
– –
BDX icon
36
Becton Dickinson
BDX
$45.6B
$15.7M 0.67%
71,522
+5,740
+9% +$1.33M
NBIX icon
37
Neurocrine Biosciences
NBIX
$18.7B
$15.4M 0.66%
216,294
+3,664
+2% +$351K
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$16.2B
$14.3M 0.61%
115,187
+4,735
+4% +$702K
NVO
39
Novo Nordisk
NVO
$228B
$13.9M 0.6%
603,800
– –
OHI icon
40
Omega Healthcare
OHI
$15B
$13.4M 0.57%
380,122
-199,663
-34% -$6.92M
SGEN
41
DELISTED
Seagen Inc. Common Stock
SGEN
$12.8M 0.55%
226,239
-53,178
-19% -$3.34M
CI icon
42
Cigna
CI
$76.1B
$12.2M 0.52%
64,089
+23,628
+58% +$4.93M
ONC
43
BeOne Medicines Ltd
ONC
$33.4B
$12M 0.51%
85,755
– –
BAX icon
44
Baxter International
BAX
$13.8B
$10.6M 0.45%
161,233
+15,193
+10% +$1.02M
XBI icon
45
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$10.4M 0.44%
144,424
+15,424
+12% +$1.24M
KYNB
46
Kyntra Bio
KYNB
$27.5M
$9.85M 0.42%
8,511
+1,383
+19% +$1.55M
BLUE
47
DELISTED
bluebird bio
BLUE
$9.76M 0.42%
7,599
+822
+12% +$1.26M
IDXX icon
48
Idexx Laboratories
IDXX
$44.1B
$9.59M 0.41%
51,575
-50,828
-50% -$10.4M
SAGE
49
DELISTED
Sage Therapeutics
SAGE
$9.43M 0.4%
98,444
-45,170
-31% -$5.17M
ZBH icon
50
Zimmer Biomet
ZBH
$18.4B
$9.25M 0.4%
91,880
-30,531
-25% -$3.43M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
  • Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
  • Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
  • Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
  • Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.